Is Humacyte Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: HUMA) stock is to Strong Buy HUMA stock.
Out of 2 analysts, 2 (100%) are recommending HUMA as a Strong Buy, 0 (0%) are recommending HUMA as a Buy, 0 (0%) are recommending HUMA as a Hold, 0 (0%) are recommending HUMA as a Sell, and 0 (0%) are recommending HUMA as a Strong Sell.
What is HUMA's forecast return on equity (ROE) for 2023-2025?
(NASDAQ: HUMA) forecast ROE is -192.93%, which is considered weak.
What is HUMA's Price Target?
According to 2 Wall Street analysts that have issued a 1 year HUMA price target, the average HUMA price target is $11.00, with the highest HUMA stock price forecast at $16.00 and the lowest HUMA stock price forecast at $6.00.
On average, Wall Street analysts predict that Humacyte's share price could reach $11.00 by Aug 31, 2024. The average Humacyte stock price prediction forecasts a potential upside of 274.15% from the current HUMA share price of $2.94.
What is HUMA's forecast return on assets (ROA) for 2023-2025?
(NASDAQ: HUMA) forecast ROA is -70.14%, which is lower than the forecast US Biotechnology industry average of 12.11%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.